Morgan Stanley Nanobiotix S.A. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Nanobiotix S.A. stock. As of the latest transaction made, Morgan Stanley holds 2 shares of NBTX stock, worth $7. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2
Previous 2
-0.0%
Holding current value
$7
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding NBTX
# of Institutions
11Shares Held
6.43MCall Options Held
0Put Options Held
0-
Johnson & Johnson New Brunswick, NJ5.62MShares$19.8 Million10.31% of portfolio
-
Perceptive Advisors LLC New York, NY555KShares$1.95 Million0.08% of portfolio
-
Black Rock Inc. New York, NY239KShares$841,3080.0% of portfolio
-
Citigroup Inc3.42KShares$12,0480.0% of portfolio
-
Ubs Group Ag3.1KShares$10,9120.0% of portfolio
About Nanobiotix S.A.
- Ticker NBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,875,900
- Market Cap $123M
- Description
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...